Active, not recruitingInterventional · Phase 2/3NCT02339571 ↗Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentPinkal DesaiPIInterventionDrug: Imetelstat Sodium · Drug: PlaceboDatesJan 2016 – Oct 2023· Results postedSponsorGeron CorporationMyelodysplastic Syndromes
RecruitingInterventional · Phase 2/3NCT03435796 ↗Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T CellsRoger N PearsePIInterventionGenetic: Gene-modified (GM) T cell therapyDatesJul 2018 – May 2043 (est.)SponsorCelgene CorporationNeoplasms
Active, not recruitingInterventional · Phase 2/3NCT03466411 ↗A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseEllen J ScherlPIInterventionDrug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Guselkumab Dose 3 · Drug: Guselkumab Dose 4 · Drug: Guselkumab Dose 5 · Drug: Guselkumab · Drug: Ustekinumab · Drug: PlaceboDatesApr 2018 – Oct 2023· Results postedSponsorJanssen Research & Development, LLCCrohn's Disease
Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction AdenocarcinomaManish A ShahPIInterventionProcedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation TherapyDatesMay 2019 – Mar 2027 (est.)SponsorECOG-ACRIN Cancer Research GroupClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more
Active, not recruitingInterventional · Phase 2/3NCT03701308 ↗A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyGail J RobozPIInterventionProcedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: UproleselanDatesMar 2019 – Oct 2024· Results postedSponsorAlliance for Clinical Trials in OncologyAcute Myeloid Leukemia
Active, not recruitingInterventional · Phase 2/3NCT04150068 ↗A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug ResistanceSorana Segal-MaurerPIInterventionDrug: Oral Lenacapavir · Drug: Oral Lenacapavir Placebo · Drug: Subcutaneous Lenacapavir · Drug: Failing ARV Regimen · Drug: Optimized Background Regimen (OBR)DatesNov 2019 – Oct 2020· Results postedSponsorGilead Sciences, Inc.HIV-1-infection
RecruitingInterventional · Phase 2/3NCT04256317 ↗A Multi-phase, Pharmacokinetics, Safety, and Efficacy Study of ASTX030 (Azacitidine and Cedazuridine) as Monotherapy in Subjects With Myeloid Neoplasm or in Combination With Venetoclax in Subjects With AML (AZTOUND Study)Gail J RobozPIInterventionDrug: Azacitidine · Drug: ASTX030 (cedazuridine + azacitidine) · Drug: Cedazuridine · Drug: VenetoclaxDatesMay 2020 – Nov 2027 (est.)SponsorAstex Pharmaceuticals, Inc.Myelodysplastic SyndromesAcute Myeloid LeukemiaMyelodysplastic Syndrome/Neoplasm+1 more
Enrolling by invitationInterventional · Phase 2/3NCT04848506 ↗A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)Daniel McDonaldPIInterventionDrug: Aficamten (5 - 20 mg)DatesMay 2021 – Mar 2029 (est.)SponsorCytokinetics, Inc.Symptomatic Hypertrophic Cardiomyopathy (HCM)
RecruitingInterventional · Phase 2/3NCT04924322 ↗Age-dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-associated Thrombosis in Critically Ill ChildrenMarianne Elizabeth NellisPIInterventionDrug: EnoxaparinDatesMay 2022 – Apr 2027 (est.)SponsorYale UniversityDeep Venous Thrombosis
RecruitingInterventional · Phase 2/3NCT05174169 ↗Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseUqba KhanPIInterventionDevice: Signatera test · Drug: mFOLFOX6 3-6 month · Drug: CAPOX 3 month · Drug: mFOLFIRINOX · Drug: mFOLFOX6 6 month · Drug: CAPOX 6 monthDatesJul 2022 – Mar 2029 (est.)SponsorNRG OncologyStage III Colon Cancer
Active, not recruitingInterventional · Phase 2/3NCT05281328 ↗A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Symptomatic Polycystic Liver DiseaseArun B. JesudianPIInterventionDrug: CAM2029 · Drug: PlaceboDatesJun 2022 – Feb 2025· Results postedSponsorCamurus ABPolycystic Liver Disease
Active, not recruitingInterventional · Phase 2/3NCT05312879 ↗A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney DiseaseJay LakkisPIInterventionDrug: VX-147 · Drug: PlaceboDatesMar 2022 – Jun 2028 (est.)SponsorVertex Pharmaceuticals, Inc.Proteinuric Kidney Disease
Active, not recruitingInterventional · Phase 2/3NCT05330182 ↗A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection RecurrenceCarl V. CrawfordPIInterventionDrug: LMN-201 · Drug: PlaceboDatesAug 2024 – Aug 2026SponsorLumen Bioscience, Inc.Clostridioides Difficile Infection
RecruitingInterventional · Phase 2/3NCT05416307 ↗A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)Justin David KanerPIInterventionDrug: ELA026DatesMay 2022 – Mar 2028 (est.)SponsorElectra Therapeutics INCSecondary Hemophagocytic Lymphohistiocytosis (sHLH)
Active, not recruitingInterventional · Phase 2/3NCT05502341 ↗An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment RegimensLok W. YungPIInterventionDrug: Bictegravir · Drug: Lenacapavir · Drug: BIC/LEN FDC · Drug: Stable Baseline RegimenDatesAug 2022 – Sep 2025· Results postedSponsorGilead Sciences, Inc.HIV-1-infection
Active, not recruitingInterventional · Phase 2/3NCT05610163 ↗The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-free Survival in Patients With Locally Advanced Rectal CancerUqba KhanPIInterventionDrug: Capecitabine · Drug: 5-fluorouracil · Drug: Leucovorin calcium · Drug: Irinotecan · Drug: Oxaliplatin · Radiation: Long Course Chemoradiotherapy · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Sigmoidoscopy · Procedure: biopsyDatesDec 2022 – Jul 2030 (est.)SponsorAlliance for Clinical Trials in OncologyStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Locally Advanced Rectal Adenocarcinoma
RecruitingInterventional · Phase 2/3NCT05691478 ↗A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed OsteosarcomaAlexander Ja-Ho ChouPIInterventionProcedure: Bone Scan · Drug: Cabozantinib S-malate · Drug: Cisplatin · Procedure: Computed Tomography · Drug: Doxorubicin Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Methotrexate · Procedure: Surgical Procedure · Procedure: X-Ray ImagingDatesMar 2023 – Mar 2030 (est.)SponsorChildren's Oncology GroupHigh Grade OsteosarcomaLocalized OsteosarcomaMetastatic Osteosarcoma+1 more
RecruitingInterventional · Phase 2/3NCT05987241 ↗MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerCora SternbergPIInterventionProcedure: Biospecimen Collection · Other: cfDNA or ctDNA Measurement · Procedure: Computed Tomography · Procedure: Cystoscopy · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Questionnaire Administration · Biological: RelatlimabDatesFeb 2024 – Sep 2030 (est.)SponsorAlliance for Clinical Trials in OncologyMuscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial Carcinoma+4 more
Active, not recruitingInterventional · Phase 2/3NCT06544733 ↗An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1Lok W. YungPIInterventionDrug: Lepetegravir · Drug: Lenacapavir pacfosacil · Drug: Placebo to Match BVY · Drug: Bictegravir/emtricitabine/tenofovir alafenamide · Drug: Lepetegravir/Lenacapavir pacfosacil FDC · Drug: Placebo to Match GS1720/GS-4182 FDCDatesAug 2024 – Jan 2028 (est.)SponsorGilead Sciences, Inc.HIV-1-Infection